TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively cor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Maas, Ralph Ja, Hoogstad-van Evert, Janneke S, Van der Meer, Jolien Mr, Mekers, Vera, Rezaeifard, Somayeh, Korman, Alan J, de Jonge, Paul Kjd, Cany, Jeannette, Woestenenk, Rob, Schaap, Nicolaas Pm, Massuger, Leon F, Jansen, Joop H, Hobo, Willemijn, Dolstra, Harry
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2020
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657585/
https://ncbi.nlm.nih.gov/pubmed/33224630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1843247
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items